Recurrent allergic bronchopulmonary aspergillosis in a patient with rheumatoid arthritis treated with etanercept and tocilizumab

References

• Lipsky PE, van der Heijde DM, Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treat-ment of rheumatoid arthritis. N Engl J Med. 2000;343:1594–602.
   PubMed Web of Science ®Google Scholar
• Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343 :1586–93.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomized trial. Lancet. 2008;371: 987–97.
   Google Scholar
• Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371:998–1006.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.
   PubMed Web of Science ®Google Scholar
• Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheuma-tology: lessons learned, future directions. Nat Rev Drug Discov. 2007;6:75–92.
   Google Scholar
• Soubani AO, Chandrasekar PH. The clinical spectrum of pul-monary aspergillosis. Chest. 2002;121:1988–99.
   PubMed Web of Science ®Google Scholar
• Patterson K, Strek ME. Allergic bronchopulmonary aspergillosis. Proc Am Thorac Soc. 2010;7:237–44.
   PubMedGoogle Scholar
• Agarwal R. Allergic bronchopulmonary aspergillosis. Chest. 2009;135:805–26.
   PubMed Web of Science ®Google Scholar
• Judson MA. Allergic bronchopulmonary aspergillosis after inf-liximab therapy for sarcoidosis. Chest. 2009;135:1358–9.
   PubMedGoogle Scholar
• Mehrad B, Strieter RM, Standiford TJ. Role of TNF-a in pul-monary host defense in murine invasive aspergillosis. J Immunol. 1999;162:1633–40.
   Google Scholar
• Cenci E, Mencacci A, Casagrande A, Mosci P, Bistoni F, Romani L. Impaired antifungal effector activity but not inflammatory cell recruitment in interleukin-6-deficient mice with invasive pul-monary aspergillosis. J Infect Dis. 2001;184:610–7.
   PubMed Web of Science ®Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.
   PubMed Web of Science ®Google Scholar
• ActemraC) (Tocilizumab) Early phase post-marketing vigilance report. Chugai Pharmaceutical Co., Ltd. 2009.
   Google Scholar
• Weaver C, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: An effector CD4 T cell lineage with regulatory T cell ties. Immunity. 2006;24: 677–88.
   Google Scholar
• Rathore VB, Johnson B, Fink JN, Kelly KJ, Greenberger PA, Kurup VP. T cell proliferation and cytokine secretion to T cell epitopes of Asp f2 in ABPA patients. Clin Immunol. 2001; 100:228–35.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of pneumonia: association with prednisone, DMARDs and anti-TNF therapy. Arthritis Rheum. 2006; 54:628–34.
   Google Scholar
• Ganassini A, Cazzadori A. Invasive pulmonary aspergillosis complicating allergic bronchopulmonary aspergillosis. Respir Med. 1995;89:143–5.
   PubMedGoogle Scholar
• Bodey GP, Glann AS. Central nervous system aspergillosis fol-lowing steroidal therapy for allergic bronchopulmonary asper-gillosis. Chest. 1993;103:299–301.
   PubMedGoogle Scholar
• Blanch-Wark PA, Hensley MJ, Saltos N, Boyle MJ, Toneguzzi RC, Simpson JL, et al. Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. J Allergy Clin Immunol. 2003;111:952–7.
   Google Scholar
• Kurup VP, Grunig G, Knutsen AP, Murali PS. Cytokine in allergic bronchopulmonary aspergillosis. Res Immunol. 1998; 149:466–77.
   PubMedGoogle Scholar
• Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Ishida H, et al. Long-term follow-up of the changes in circulating cyto-kines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after mono-clonal anti-TNFa antibody therapy. J Clin Immunol. 1999; 19:305–13.
   PubMed Web of Science ®Google Scholar
• Wang J, Homer RJ, Chen Q, Elias JA. Endogenous and exoge-nous IL-6 inhibit aeroallergen-induced 'Th2 inflammation. J Immunol. 2000;165:4051–61.
   PubMed Web of Science ®Google Scholar
• Doganci A, Eigenbrod T, Krug N, De Sanctis GT, Hausding M, Erpenbeck VJ, et al. The IL-6R a chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest. 2005;115: 313–25.
   Google Scholar
• Ohshima S, Saeki Y, Mima T, Sasai M, Nishioka K, Nomura S, et al. Interleukin-6 plays a key role in the development of anti-gen-induced arthritis. Proc Natl Acad Sci USA. 1998;95:8222–6.
   PubMed Web of Science ®Google Scholar
• Jain B, Rubinstein I, Robbins RA, Sisson JH. TNF-alpha and IL-1 beta upregulate nitric oxide-dependent ciliary motility in bovine airway epithelium. Am J Physiol. 1995;268:L911–7.
   PubMed Web of Science ®Google Scholar
• Moghaddam SJ, Clement CG, De la Garza MM, Zou X, Travis EL, Young HWJ, et al. Haemophilus influenza lysate induces aspects of the chronic obstructive pulmonary disease phenotype. Am J Respir Cell Mol Biol. 2008;38:629–38.
   Google Scholar
• Kida H, Yoshida M, Hoshino S, Inoue K, Yano Y, Yanagita M, et al. Protective role of IL-6 on alveolar epithelial cell death induced by hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol. 2005;288:342–9.
   PubMed Web of Science ®Google Scholar
• Kida H, Mucenski ML, 'Thitoff AR, Le Cras TD, Park KS, Ikegami M, et al. Gp130-Stat3 regulates epithelial cell migration and is required for repair of the bronchiolar epithelium. Am J Pathol. 2008;172: 1542–54.
   Google Scholar
• Neveu WA, Allard JB, Dienz 0, Wargo MJ, Ciliberto G, Whittaker LA, et al. IL-6 is required for airway mucus production induced by inhaled fungal allergens. J Immunol. 2009;183: 1732–8.
   Google Scholar